Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

This randomized, double-blind study assessed the antifracture efficacy and safety of intermittent intravenous (IV) ibandronate versus oral daily risedronate in Japanese patients with primary osteoporosis. Ambulatory patients aged ≥60 years were randomized to receive 0.5 or 1 mg/month IV ibandronate...

Full description

Bibliographic Details
Main Authors: Nakamura, Toshitaka, Nakano, Tetsuo, Ito, Masako, Hagino, Hiroshi, Hashimoto, Junko, Tobinai, Masato, Mizunuma, Hideki
Format: Online
Language:English
Published: Springer US 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717162/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717162/

Similar Items